Inventiva (NASDAQ:IVA) Shares Gap Down - Here's What Happened

Key Points

• Inventiva shares opened sharply lower, falling from a prior close of $3.69 to $3.38 before recovering to around $3.72, with trading volume exceeding 1.5 million shares.
• Analyst sentiment remains broadly positive: the stock has an average “Buy” rating and a consensus price target of $15.14, despite one analyst maintaining a sell rating.
• Inventiva reported a quarterly loss of $0.14 per share on $0.75 million in revenue, while institutional investors hold approximately 19.06% of the company.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva shares last traded at $3.7150, with a volume of 1,531,710 shares.

Analysts Set New Price Targets

IVA has been the topic of a number of research analyst reports. Guggenheim boosted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research report on Friday, July 17th. They set an "overweight" rating on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a report on Friday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $15.14.

Inventiva Trading Down 2.8%

The company has a debt-to-equity ratio of 0.90, a current ratio of 3.81 and a quick ratio of 3.16. The stock's 50-day moving average price is $4.37 and its two-hundred day moving average price is $4.69.

Inventiva (NASDAQ:IVA - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter. On average, analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. NEXTBio Capital Management LP bought a new stake in Inventiva during the 4th quarter valued at about $6,039,000. Propel Bio Management LLC bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $1,155,000. Seven Fleet Capital Management LP purchased a new position in Inventiva in the 1st quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd bought a new position in Inventiva in the 4th quarter valued at approximately $603,000. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.